People Want an Alzheimer’s Drug. This Isn’t the One.
An F.D.A. sign-off for aducanumab would make finding a good treatment harder.
Continue Reading https://www.nytimes.comAn F.D.A. sign-off for aducanumab would make finding a good treatment harder.
Continue Reading https://www.nytimes.com
Join the Discussion